Table 2.
Results of antibody response following vaccination in Cancer Patients: titer of neutralizing antibodies expressed as median (25th, 75th percentiles) (in BAU/mL) according to participant characteristics (at baseline) and date of sample collection regarding the vaccine injection.
| D0–D14 | D15–D29 | D30–D44 | D45–D59 | D60–D74 | D75–D90 | |
|---|---|---|---|---|---|---|
| All CP | ||||||
| 1st injection | <4.81 (<4.81, <4.81)/49 | 32 (<4.81, 187)/35 | 18 (4, 30)/11 | 97 (62, 341)/4 | n = 2 | n = 1 |
| 2nd injection | 138 (32, 450)/40 | 1600 (505, >2080)/43 | 1560 (485, >2080)/43 | 1270 (364, 2070)/24 | 728 (358, 1538)/26 | 730 (423, 1383)/32 |
| CP with chemotherapy | ||||||
| 1st injection | <4.81 (<4.81, <4.81)/26 | 23 (<4.81, 81)/18 | 22 (17, 30)/7 | n = 1 | n = 1 | n = 1 |
| 2nd injection | 103 (26, 520)/28 | 1910 (703, >2080)/29 | 1835 (656, >2080)/26 | 1670 (760, 2015)/11 | 782 (315, 1840)/15 | 810 (494, 1255)/19 |
| CP with immunotherapy | ||||||
| 1st injection | <4.81 (<4.81, <4.81)/7 | 9.8 (<4.81, 77)/6 | n = 2 | n = 1 | No serology | No serology |
| 2nd injection | 79 (8, 172)/4 | 528 (296, 1371.5)/6 | 2030 (716, >2080)/7 | 980 (472, 1810)/7 | 142 (93, 300)/3 | 817 (481, 1290)/6 |
| Women CP | ||||||
| 1st injection | <4.81 (<4.81, <4.81)/31 | 6.8 (<4.81, 264.5)/26 | 16.6 (6.4, 29.7)/8 | n = 2 | n = 2 | n = 1 |
| 2nd injection | 174 (46.2, 565)/24 | 1890 (716.8, >2080)/34 | 1860 (634, >2080)/30 | 1270 (467, 1992.5)/20 | 776 (421, 1667.5)/20 | 1010 (492, 1430)/21 |
| Men CP | ||||||
| 1st injection | <4.81 (<4.81, <4.81)/18 | <4.81 (<4.81, 13.1)/9 | 21.7 (10.8, 47.9)/3 | n = 2 | No serology | No serology |
| 2nd injection | 93.9 (4.9, 215.8)/16 | 455 (380, 1190)/9 | 814 (386, 1170)/13 | 1251.5 (307.8, 2100)/4 | 526 (219.8, 1027.2)/6 | 576 (308, 834.5)/11 |
| CP aged 60 y and over | ||||||
| 1st injection | <4.81 (<4.81, <4.81)/24 | 11.9 (<4.81, 77.6)/24 | 18 (8.6, 29.3)/5 | n = 2 | n = 1 | No serology |
| 2nd injection | 101.5 (9.6, 258.5)/24 | 1500 (464.5, >2080)/22 | 1140 (303, >2080)/23 | 989 (123.1, 1937.5)/14 | 599 (304, 1170)/17 | 576 (241, 1015)/19 |
| CP younger than 60 y | ||||||
| 1st injection | <4.81 (<4.81, <4.81)/25 | 85.6 (49.2, 252)/11 | 18.5 (3.8, 28.4)/6 | n = 2 | n = 1 | n = 1 |
| 2nd injection | 230.5 (46.2, 616.2)/16 | 1910 (550, >2080)/21 | 1800 (778.8, >2080)/20 | 1745 (660.8, >2080)/10 | 1240 (685, 2050)/9 | 1210 (810, 1430)/13 |
CP: cancer patients; n: number of available serological titers; CT: chemotherapy; IT: immunotherapy.